July 2015 By Richard Jefferys Introduction The rise to prominence of cure research has continued over the past year, with every major scientific conference on HIV now featuring sessions and presentations on the topic. The U.S. National Institute of Allergy…
July 2015 By Tim Horn and Richard Jefferys Though global HIV incidence has declined by an estimated 33% since 2001, more than 2 million people continue to be infected with the virus every year – approximately 6,000 new infections every…
July 2015 By Polly Clayden Introduction The big news since the 2014 Pipeline Report is that there is finally a solid form of lopinavir/ritonavir (LPV/r) suitable for infants and young children. On 21 May 2015, the United States Food and…
July 2015 By Polly Clayden The most striking news since the 2014 Pipeline Report is from the START (Strategic Timing of AntiRetroviral Treatment) study.1 We now have evidence from a large, randomized, controlled trial to show that CD4 count is…
July 2015 By Simon Collins and Tim Horn INTRODUCTION As a global community of people living with HIV, our needs from the antiretroviral (ARV) pipeline have changed considerably over the last 20 years. Antiretroviral treatment (ART), particularly for people starting treatment,…
THIS REPORT IS DEDICATED TO Tireless Champion of Disadvantaged and Vulnerable People Ana Isabel Charle (1979–2015) and Pioneering HIV Researcher and Activist Joseph Albert Marie “Joep” Lange (1954–2014)
July 15, 2016 By Mark Harrington Due to recent transitions in the TAG HCV Project [1], we did not complete a comprehensive update on hepatitis C virus (HCV) pipeline. Here are a few highlights in HCV regulation, access, and policy…
July 15, 2016 By Lindsay McKenna INTRODUCTION The roster of enrolling and planned pediatric tuberculosis (TB) treatment studies is growing. Emerging results from pharmacokinetics (PK) and safety studies continue to inform optimal dosing strategies in children and to highlight areas…
July 15, 2016 By Erica Lessem In the past year, the development of new tuberculosis (TB) drug candidates experienced some setbacks as well as some wise pruning, with the unexpected suspension of enrollment in STAND (a phase III combination trial…
July 15, 2016 By Mike Frick After decades of receiving short shrift from most national TB programs and international organizations, tuberculosis (TB) prevention is finally coming into the mainstream. In 2015, the World Health Organization (WHO) published its first-ever Guidelines…